›1.independentA dosage form for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a)…+7
A dosage form for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a) a therapeutically effective amount of a drug; (b) at least one effervescent penetration enhancer; wherein said at least one effervescent penetration enhancer is present in an amount sufficient to increase the penetration of said drug across said target area of said gastrointestinal tract to permit delivery of a therapeutically effective amount of said drug; (c) a pH adjusting substance; and (d) an enteric coating maintained over said drug, said at least one effervescent penetration enhancer and said pH adjusting substance; wherein said enteric coating prevents the release of said drug, said at least one effervescent penetration enhancer and said pH adjusting substance until a time at which said dosage form reaches said target area in said gastrointestinal tract.
›2.↳ 1The dosage form of claim 1, wherein said amount of said at least one effervescent penetration enhancer is equal to about two times the amount of said …d2
The dosage form of claim 1, wherein said amount of said at least one effervescent penetration enhancer is equal to about two times the amount of said drug.
›3.↳ 1The dosage form of claim 1, wherein said amount of said at least one effervescent penetration enhancer is equal to about three times the amount of sai…d2
The dosage form of claim 1, wherein said amount of said at least one effervescent penetration enhancer is equal to about three times the amount of said drug.
›16.↳ 1The dosage form of claim 1, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said effervesc…d2+3
The dosage form of claim 1, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said effervescent couple comprising an acid or equivalent thereof and a base or equivalent thereof.
›17.↳ 16The dosage form of claim 16 wherein said base is sodium bicarbonate.d3
The dosage form of claim 16 wherein said base is sodium bicarbonate.
›18.↳ 16The dosage form of claim 16 wherein said base or equivalent thereof is present in an amount equal to about two times the amount of said drug; and said…d3
The dosage form of claim 16 wherein said base or equivalent thereof is present in an amount equal to about two times the amount of said drug; and said acid is present in an amount approximately equimolar to said base.
›19.↳ 16The dosage form of claim 16 wherein said base or equivalent thereof is present in an amount equal to about three times the amount of said drug; and sa…d3
The dosage form of claim 16 wherein said base or equivalent thereof is present in an amount equal to about three times the amount of said drug; and said acid is present in an amount approximately equimolar to said base.
›20.↳ 1The dosage form of claim 1 wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract.d2
The dosage form of claim 1 wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract.
›4.independentA tablet for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a) a th…
A tablet for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a) a therapeutically effective amount of a drug; (b) at least one effervescent penetration enhancer; wherein said at least one effervescent penetration enhancer is present in an amount sufficient to increase the penetration of said drug across said target area of said gastrointestinal tract to permit delivery of a therapeutically effective amount of said drug; (c) an enteric coating maintained over said drug; and said at least one effervescent penetration enhancer; wherein said enteric coating prevents the release of said drug and said at least one effervescent penetration enhancer until a time at which said tablet reaches said target area in said gastrointestinal tract; said tablet containing a biconcave zone central to two outer zones; wherein said drug and said effervescent penetration enhancer are located in said biconcave zone.
›5.independentmultiple · 1, 2, 3The dosage form of any one of claims 1-3, further comprising a bioadhesive, wherein said bioadhesive increases contact time between said drug and a mu…+1
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 1-3, further comprising a bioadhesive, wherein said bioadhesive increases contact time between said drug and a mucosa layer of said target area.
›6.↳ 5The dosage form of claim 5, wherein said bioadhesive is contained in a portion of said dosage form external to said drug.d2
The dosage form of claim 5, wherein said bioadhesive is contained in a portion of said dosage form external to said drug.
›7.independentmultiple · 1, 2, 3The dosage form of any one of claims 1-3, further comprising at least one noneffervescent penetration enhancer.
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 1-3, further comprising at least one noneffervescent penetration enhancer.
›8.independentmultiple · 1, 2, 3The dosage form of any one of claims 1-3 further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid disp…
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 1-3 further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid dispersion of said drug to said target area of said gastrointestinal tract.
›9.independentmultiple · 1, 2, 3The dosage form of any of claims 1-3, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area of said…
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any of claims 1-3, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area of said gastrointestinal tract to release said drug, said effervescent penetration enhancer and said pH adjusting substance.
›10.independentmultiple · 1, 2, 3The dosage form of any one of claims 1-3, wherein said dosage form is a tablet.+2
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 1-3, wherein said dosage form is a tablet.
›14.↳ 10The dosage form of claim 10, wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug, said effervescent penetratio…d2+1
The dosage form of claim 10, wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug, said effervescent penetration enhancer and said pH adjusting substance are located in said biconcave zone.
›15.↳ 14The dosage form of claim 14, wherein a bioadhesive is contained in said two outer zones.d3
The dosage form of claim 14, wherein a bioadhesive is contained in said two outer zones.
›11.independentmultiple · 1, 2, 3The dosage form of any one of claims 1-3, wherein said dosage form is a capsule.
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 1-3, wherein said dosage form is a capsule.
›12.independentmultiple · 1, 2, 3The dosage form of any one of claims 1-3, wherein said dosage form is in the form of granules.
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 1-3, wherein said dosage form is in the form of granules.
›13.independentmultiple · 1, 2, 3The dosage form of any one of claims 1-3, wherein said dosage from is in the form of pellets.
Multiple dependency — claims 1, 2, 3. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 1-3, wherein said dosage from is in the form of pellets.
›21.independentA dosage form for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a)…+7
A dosage form for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a) a therapeutically effective amount of a drug; (b) at least one effervescent penetration enhancer; wherein said at least one effervescent penetration enhancer is present in an amount sufficient to increase the penetration of said drug across said target area of said gastrointestinal tract to permit delivery of a therapeutically effective amount of said drug; (c) at least one noneffervescent penetration enhancer; and (d) an enteric coating maintained over said drug, said at least one effervescent penetration enhancer and said at least one noneffervescent penetration enhancer; wherein said enteric coating prevents the release of said drug, said at least one effervescent penetration enhancer and said at least one noneffervescent penetration enhancer until a time at which said dosage form reaches said target area in said gastrointestinal tract.
›22.↳ 21The dosage form of claim 21, wherein said amount of said at least one effervescent penetration enhancer is equal to about-two times the amount of said…d2
The dosage form of claim 21, wherein said amount of said at least one effervescent penetration enhancer is equal to about-two times the amount of said drug.
›23.↳ 21The dosage form of claim 21, wherein said amount of said at least one effervescent penetration enhancer is equal to about three times the amount of sa…d2
The dosage form of claim 21, wherein said amount of said at least one effervescent penetration enhancer is equal to about three times the amount of said drug.
›54.↳ 21The dosage form of claim 21, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said efferves…d2+3
The dosage form of claim 21, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said effervescent couple comprising an acid or equivalent thereof and a base or equivalent thereof.
›55.↳ 54The dosage form of claim 54, wherein said base is sodium bicarbonate.d3
The dosage form of claim 54, wherein said base is sodium bicarbonate.
›56.↳ 54The dosage form of claim 54, wherein said base or equivalent thereof is present in an amount equal to about two times the amount of said drug; and sai…d3
The dosage form of claim 54, wherein said base or equivalent thereof is present in an amount equal to about two times the amount of said drug; and said acid is present in an amount approximately equimolar to said base.
›57.↳ 54The dosage form of claim 54, wherein said base or equivalent thereof is present in an amount equal to about three times the amount of said drug; and s…d3
The dosage form of claim 54, wherein said base or equivalent thereof is present in an amount equal to about three times the amount of said drug; and said acid is present in an amount approximately equimolar to said base.
›58.↳ 21The dosage form of claim 21, wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract.d2
The dosage form of claim 21, wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract.
›24.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, further comprising a pH adjusting substance.
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, further comprising a pH adjusting substance.
›25.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, further comprising a bioadhesive, wherein said bioadhesive increases contact time between said drug and a …+1
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, further comprising a bioadhesive, wherein said bioadhesive increases contact time between said drug and a mucosa layer of said target area.
›45.↳ 25The dosage form of claim 25, wherein said bioadhesive is contained in a portion of said dosage form external to said drug.d2
The dosage form of claim 25, wherein said bioadhesive is contained in a portion of said dosage form external to said drug.
›26.independentA dosage form for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a)…+8
A dosage form for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising: (a) a therapeutically effective amount of a drug; (b) at least one effervescent penetration enhancer; wherein said at least one effervescent penetration enhancer is present in an amount sufficient to increase the penetration of said drug across said target area of said gastrointestinal tract to permit delivery of a therapeutically effective amount of said drug; (c) a bioadhesive; wherein said bioadhesive increases contact time between said drug and a mucosa layer of said target area; and (d) an enteric coating maintained over said drug, said at least one effervescent penetration enhancer and said bioadhesive; wherein said enteric coating prevents the release of said drug and said at least one effervescent penetration enhancer and the exposure of said bioadhesive until a time at which said dosage form reaches said target area in said gastrointestinal tract.
›27.↳ 26The dosage form of claim 26, wherein said amount of said at least one effervescent penetration enhancer is equal to about two times the amount of said…d2
The dosage form of claim 26, wherein said amount of said at least one effervescent penetration enhancer is equal to about two times the amount of said drug.
›28.↳ 26The dosage form of claim 26, wherein said amount of said at least one effervescent penetration enhancer is equal to about three times the amount of sa…d2
The dosage form of claim 26, wherein said amount of said at least one effervescent penetration enhancer is equal to about three times the amount of said drug.
›30.↳ 26The dosage form of claim 26, wherein said bioadhesive is contained in a portion of said dosage form external to said drug.d2
The dosage form of claim 26, wherein said bioadhesive is contained in a portion of said dosage form external to said drug.
›40.↳ 26The dosage form of claim 26, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said efferves…d2+4
The dosage form of claim 26, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said effervescent couple comprising an acid or equivalent thereof and a base or equivalent thereof.
›41.↳ 40The dosage form of claim 40, wherein said base is sodium bicarbonate.d3
The dosage form of claim 40, wherein said base is sodium bicarbonate.
›42.↳ 40The dosage form of claim 40, wherein said base or equivalent thereof is present in an amount equal to about two times the amount of said drug; and sai…d3
The dosage form of claim 40, wherein said base or equivalent thereof is present in an amount equal to about two times the amount of said drug; and said acid is present in an amount approximately equimolar to said base.
›43.↳ 40The dosage form of claim 40, wherein said base or equivalent thereof is present in an amount equal to about three times the amount of said drug; and s…d3
The dosage form of claim 40, wherein said base or equivalent thereof is present in an amount equal to about three times the amount of said drug; and said acid is present in an amount approximately equimolar to said base.
›44.↳ 40The dosage form of claim 40, wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract.d3
The dosage form of claim 40, wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract.
›29.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, further comprising a pH adjusting substance.
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, further comprising a pH adjusting substance.
›31.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, further comprising at least one noneffervescent penetration enhancer.
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, further comprising at least one noneffervescent penetration enhancer.
›32.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid d…
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid dispersion of said drug to said target area of said gastrointestinal tract.
›33.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area o…
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area of the gastrointestinal tract to release said drug and said effervescent penetration enhancer.
›34.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, wherein said dosage form is a tablet.+2
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, wherein said dosage form is a tablet.
›38.↳ 34The dosage form of claim 34, wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug and said effervescent penetra…d2+1
The dosage form of claim 34, wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug and said effervescent penetration enhancer are located in said biconcave zone.
›39.↳ 38The dosage form of claim 38, wherein said bioadhesive is contained in said two outer zones.d3
The dosage form of claim 38, wherein said bioadhesive is contained in said two outer zones.
›35.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, wherein said dosage form is a capsule.
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, wherein said dosage form is a capsule.
›36.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, wherein said dosage form is in the form of granules.
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, wherein said dosage form is in the form of granules.
›37.independentmultiple · 26, 27, 28The dosage form of any one of claims 26-28, wherein said dosage form is in the form of pellets.
Multiple dependency — claims 26, 27, 28. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 26-28, wherein said dosage form is in the form of pellets.
›46.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid d…
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid dispersion of said drug to said target area of said gastrointestinal tract.
›47.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area o…
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area of the gastrointestinal tract to release said drug, said effervescent penetration enhancer, and said noneffervescent penetration enhancer.
›48.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, wherein said dosage form is a tablet.+3
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, wherein said dosage form is a tablet.
›52.↳ 48The dosage form of claim 48, wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug, said effervescent penetratio…d2+2
The dosage form of claim 48, wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug, said effervescent penetration enhancer and said noneffervescent penetration enhancer are located in said biconcave zone.
›53.↳ 52The dosage form of claim 52, wherein said two outer zones contain a bioadhesive.d3
The dosage form of claim 52, wherein said two outer zones contain a bioadhesive.
›59.↳ 52The tablet of claim 52, wherein said two outer zones contain a bioadhesive.d3
The tablet of claim 52, wherein said two outer zones contain a bioadhesive.
›49.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, wherein said dosage form is a capsule.
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, wherein said dosage form is a capsule.
›50.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, wherein said dosage form is in the form of granules.
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, wherein said dosage form is in the form of granules.
›51.independentmultiple · 21, 22, 23The dosage form of any one of claims 21-23, wherein said dosage form is in the form of pellets.
Multiple dependency — claims 21, 22, 23. Shown here under ; it stands on every one of them.
The dosage form of any one of claims 21-23, wherein said dosage form is in the form of pellets.
